Cadila Healthcare Limited has informed the Exchange about press release dated 07-Mar-2022 titled Zydus to launch Oxemia (Desidustat) a breakthrough treatment for Anemia in patients suffering from Chronic Kidney Disease (CKD)
Press Release Mar 07 2022
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Oxemia is an oral tablet that serves as an alternative to injectable treatments and has received approval from the Drug Controller General of India. The drug has shown positive results in clinical trials, improving hemoglobin levels and offering a safer treatment option for patients. This development marks a significant milestone for Zydus in its innovation journey within the nephrology segment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 23 2022
- Press Release Feb 14 2022
- Press Release Feb 02 2022
- Press Release Jan 20 2022
- Press Release Dec 31 2021
Later from Zydus Lifesciences
- Press Release Mar 08 2022
- Press Release Mar 09 2022
- Press Release Mar 14 2022
- Press Release Mar 21 2022
- Press Release Apr 01 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences